🔹 Adj EPS: $8.84 (Est. $9.07) 🔴
🔹 Revenue: $49.4 B (Est. $48.14B) 🟢; +14.3% YoY
FY25 Guidance
🔹Adj EPS: $30.00 (Est. $34.48) 🔴
Q2 Segment / Product Results
🔹 Health Benefits revenue: $41.6 B; UP +12% YoY
🔹 Health Benefits operating margin: 3.8%; DOWN –200 bp YoY
🔹 Carelon revenue: $18.1 B; UP +36% YoY
🔹 Carelon adjusted operating margin: 5.2%; DOWN –40 bp YoY
Other Metrics
🔹 Benefit expense ratio: 88.9%; UP +260 bp YoY
🔹 Operating expense ratio: 10.1%; DOWN –160 bp YoY
🔹 Returned $2.0 B capital to shareholders YTD
CEO Commentary
🔸 “In the second quarter, Elevance Health made meaningful progress in delivering an experience that is simple and personal to those we serve, while advancing our efforts to enhance efficiency across the healthcare system… With the embedded earnings power of our diversified Health Benefits and Carelon businesses, we remain confident in achieving at least 12% average annual growth in adjusted diluted EPS over time.” – Gail K. Boudreaux